1-4 of 4
Ming-Hui Tai
Close
Sort by
Journal Articles

Real-World Patient Characteristics and Treatment Outcomes Among Newly Diagnosed Multiple Myeloma Patients Initiating Daratumumab, Lenalidomide, and Dexamethasone As First-Line Therapy

Ming-Hui Tai, Qian Cai, Alex Z. Fu, Vipin Khare, Shuchita Kaila
Journal: Blood
Blood (2021) 138 (Supplement 1): 1979.
https://doi.org/10.1182/blood-2021-149002
Published: 2021
Journal Articles

Patient Characteristics, Treatment Patterns and Outcomes Among Black and White Patients with Multiple Myeloma Initiating Daratumumab: A Real-World Chart Review Study

Shebli Atrash, Philippe Thompson-Leduc, Ming-Hui Tai, Shuchita Kaila, Kathleen Gray, Isabelle Ghelerter, Marie-Hélène Lafeuille, Patrick Lefebvre, Adriana C Rossi
Journal: Blood
Blood (2021) 138 (Supplement 1): 1965.
https://doi.org/10.1182/blood-2021-145941
Published: 2021
Journal Articles

Use of Anti-Infective Prophylaxis in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Initiating Treatment with Daratumumab

Ming-Hui Tai, PhD, Eric M. Ammann, PhD, Shuchita Kaila, PhD, Christopher Pericone, Ajaybir Singh, Thomas S. Lin, MD PhD, Faith E. Davies
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-134086
Published: 2020
Journal Articles

Early Molecular Response (EMR) with Frontline Treatment Is a Significant Predictor of Long-Term BCR-ABL Transcript Levels in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML) in Chronic Phase

Giuseppe Saglio, Sonya J. Snedecor, PhD, Xiang Ji, Ming-Hui Tai, BPharm, MHPA, PhD, David Ray, PharmD, MBA, Estella Mendelson, BSRN, MBA, Aby Buchbinder, Pascal Edrich, Francois-Xavier Mahon, MD PhD Professor
Journal: Blood
Blood (2015) 126 (23): 1579.
https://doi.org/10.1182/blood.V126.23.1579.1579
Published: 2015